Protagonist Therapeutics Debt to Equity Ratio 2015-2022 | PTGX

Current and historical debt to equity ratio values for Protagonist Therapeutics (PTGX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Protagonist Therapeutics debt/equity for the three months ending March 31, 2022 was 0.00.
Protagonist Therapeutics Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.05B $0.30B 0.15
2021-12-31 $0.05B $0.30B 0.16
2021-09-30 $0.04B $0.33B 0.13
2021-06-30 $0.05B $0.36B 0.13
2021-03-31 $0.04B $0.26B 0.15
2020-12-31 $0.05B $0.28B 0.16
2020-09-30 $0.05B $0.17B 0.28
2020-06-30 $0.06B $0.17B 0.34
2020-03-31 $0.07B $0.06B 1.15
2019-12-31 $0.08B $0.08B 0.94
2019-09-30 $0.06B $0.10B 0.62
2019-06-30 $0.06B $0.08B 0.76
2019-03-31 $0.03B $0.10B 0.31
2018-12-31 $0.03B $0.11B 0.24
2018-09-30 $0.03B $0.12B 0.20
2018-06-30 $0.03B $0.11B 0.28
2018-03-31 $0.04B $0.12B 0.30
2017-12-31 $0.04B $0.12B 0.36
2017-09-30 $0.05B $0.06B 0.91
2017-06-30 $0.01B $0.06B 0.16
2017-03-31 $0.01B $0.08B 0.10
2016-12-31 $0.01B $0.09B 0.07
2016-09-30 $0.01B $0.10B 0.06
2016-06-30 $0.07B $-0.05B -1.53
2016-03-31 $0.00B $0.00B 0.00
2015-12-31 $0.00B 0.00
2015-09-30 $0.00B $0.00B 0.00
2015-06-30 $0.00B $0.00B 0.00
2014-12-31 $0.02B $-0.01B -1.82
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.375B $0.027B
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00